trending Market Intelligence /marketintelligence/en/news-insights/trending/yuwjq1z-rnujgxekdsfaua2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

US appeals court denies Hikma unit's rehearing request in Vanda patent suit

Blog

Global M&A Infographic Q1 2021

Blog

Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge

Blog

COVID-19 Impact & Recovery: Private Equity

COVID-19 Impact & Recovery: Corporates


US appeals court denies Hikma unit's rehearing request in Vanda patent suit

The U.S. Court of Appeals for the Federal Circuit denied West-Ward Pharmaceutical Corp.'s petitions challenging the outcome of a patent infringement suit.

The subsidiary of London-based Hikma Pharmaceuticals PLC was seeking a rehearing on the court's earlier decision to uphold the U.S. District Court for the District of Delaware's ruling that said it had infringed on U.S. patent number 8,586,610 covering Vanda Pharmaceuticals Inc.'s schizophrenia drug Fanapt.

Washington, D.C.-based Vanda said the patent will expire Nov. 2, 2027.